English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine Clinical Trials
Avance Clinical 宣布收购北美 CRO扩大生物技术的后期服务
Sep 06, 2022 14:00 HKT
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs
Sep 06, 2022 13:00 HKT
글로벌데이터의 새로운 보고서 아시아태평양 지역, 글로벌 임상 시험의 50 % 유치
Sep 06, 2022 07:00 HKT
Novotech参加2022年ESMO大会 - 新数据显示亚太地区的肿瘤学试验增长100%
Sep 06, 2022 07:00 HKT
Novotech參加2022年ESMO大會 - 新數據顯示亞太地區的腫瘤學試驗增長100%
Sep 06, 2022 07:00 HKT
Novotech at ESMO Congress 2022 - New Data Shows 100% Oncology Trials Growth in APAC
Sep 05, 2022 18:00 HKT
亚太地区吸引了50%的全球临床试验 根据新的GlobalData报告
Sep 02, 2022 21:00 HKT
亞太地區吸引了50%的全球臨床試驗 根據新的GlobalData報告
Sep 02, 2022 21:00 HKT
APAC Attracts 50% of Global Clinical Trials According to New GlobalData Report
Sep 02, 2022 14:00 HKT
Glenn Haifer 博士和 Ampersand Capital Partners 收購澳大利亞生物製品 CDMO Luina Bio,更名為 AcuraBio
Aug 31, 2022 12:00 HKT
글렌 하이퍼 박사와 앰퍼샌드 캐피탈 파트너스, 호주의 바이오로직스 CDMO 루이나 바이오 인수 후 아쿠라바이오로 리브랜딩
Aug 31, 2022 12:00 HKT
Glenn Haifer 博士和 Ampersand Capital Partners 收购澳大利亚生物制品 CDMO Luina Bio,更名为 AcuraBio
Aug 31, 2022 12:00 HKT
아방스 클리니컬, 인포마파마인텔리전스 어워드 2022에서 올해의 바이오테크 기업상 후원
Aug 31, 2022 11:00 HKT
Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding as AcuraBio
Aug 30, 2022 21:00 HKT
Avance 临床赞助商在 2022 年 Informa Pharma Intelligence Awards 中获得年度生物技术公司奖
Aug 30, 2022 06:00 HKT
Avance 臨床贊助商在 2022 年 Informa Pharma Intelligence Awards 中獲得年度生物技術公司獎
Aug 30, 2022 06:00 HKT
Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022
Aug 29, 2022 18:00 HKT
Legend Capital Portfolio: China-leading CRO Enterprise R&G Pharmastudies Listed on the ChiNext Market Successfully
Aug 15, 2022 16:50 HKT
Virios Therapeutics: The 'Virus Hypothesis' That Stands to Change the Lives of 10M Americans
Aug 09, 2022 20:30 HKT
노보텍의 유연 근무 정책, 최고 유연 근무 프로그램의 ‘2022년 우수상’ 최종 후보로 선정
Jul 26, 2022 20:00 HKT
<< Previous  Next >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: